Publications by authors named "Steve F Poon"

Claim this Profile
S
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N'-arylpiperazine series.
Nobuko Nishimura, Mark H Norman, Longbin Liu, Kevin C Yang, Kate S Ashton, Steve F Poon

J Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept.
Kate S Ashton, Kristin L Andrews, Marian C Bryan, Jie Chen, Kui Chen, Steve F Poon

J Med Chem· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles.
David J St Jean, Kate S Ashton, Michael D Bartberger, Jie Chen, Samer Chmait, Steve F Poon

J Med Chem· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism.
Paul M Wehn, Paul E Harrington, Timothy J Carlson, James Davis, Pierre Deprez, Steve F Poon

Bioorg Med Chem Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2.
Kate S Ashton, David J St Jean, Steve F Poon, Matthew R Lee, John G Allen

Bioorg Med Chem Lett· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core.
Paul E Harrington, David J St Jean, Jeffrey Clarine, Thomas S Coulter, Michael Croghan, Steve F Poon

Bioorg Med Chem Lett· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics.
Steve F Poon, David J St Jean, Paul E Harrington, Charles Henley, James Davis

J Med Chem· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A tandem cross-coupling/S(N)Ar approach to functionalized carbazoles.
David J St Jean, Steve F Poon, Jamie L Schwarzbach

Org Lett· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
Lida R Tehrani, Nicholas D Smith, Dehua Huang, Steve F Poon, Jeffrey R Roppe

Bioorg Med Chem Lett· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel approach to pro-drugs of lactones: water soluble imidate and ortho-ester derivatives of a furanone-based COX-2 selective inhibitor.
Steve F Poon, Nicholas Stock, Joseph E Payne, Angela R McGuire, Brian Stearns

Bioorg Med Chem Lett· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
Dehua Huang, Steve F Poon, Deborah F Chapman, Janice Chung, Merryl Cramer

Bioorg Med Chem Lett· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
Steve F Poon, Brian W Eastman, Deborah F Chapman, Janice Chung, Merryl Cramer

Bioorg Med Chem Lett· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
Nicholas D Smith, Steve F Poon, Dehua Huang, Mitchell Green, Christopher King

Bioorg Med Chem Lett· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis